MA27710A1 - Formulations pharmaceutiques liquides de palonosetrone - Google Patents

Formulations pharmaceutiques liquides de palonosetrone

Info

Publication number
MA27710A1
MA27710A1 MA28440A MA28440A MA27710A1 MA 27710 A1 MA27710 A1 MA 27710A1 MA 28440 A MA28440 A MA 28440A MA 28440 A MA28440 A MA 28440A MA 27710 A1 MA27710 A1 MA 27710A1
Authority
MA
Morocco
Prior art keywords
palonosetrone
pharmaceutical formulations
liquid pharmaceutical
palonosetronone
formulations
Prior art date
Application number
MA28440A
Other languages
English (en)
Inventor
Calderari Giorgio
Bonadeo Daniele
Cannella Roberta
Enrico Braglia
Ricardo Braglia
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32825409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27710(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of MA27710A1 publication Critical patent/MA27710A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B55/00—Preserving, protecting or purifying packages or package contents in association with packaging
    • B65B55/02—Sterilising, e.g. of complete packages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mechanical Engineering (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des formulations liquides de palonosétrone stables au stockage en vue de réduire, par la palonosétrone, les vomissements provoqués par la chimiothérapie et la radiothérapie. Les formulations sont utilisées notamment pour la préparation de médicaments liquides pouvant être administrés par voie orale et intraveineuse.
MA28440A 2003-01-30 2005-08-12 Formulations pharmaceutiques liquides de palonosetrone MA27710A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44435103P 2003-01-30 2003-01-30

Publications (1)

Publication Number Publication Date
MA27710A1 true MA27710A1 (fr) 2006-01-02

Family

ID=32825409

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28440A MA27710A1 (fr) 2003-01-30 2005-08-12 Formulations pharmaceutiques liquides de palonosetrone

Country Status (41)

Country Link
US (9) US7947724B2 (fr)
EP (2) EP2008659A1 (fr)
JP (2) JP5461763B2 (fr)
KR (1) KR101113084B1 (fr)
CN (2) CN1758911A (fr)
AP (1) AP2110A (fr)
AR (1) AR042977A1 (fr)
AT (1) ATE410167T1 (fr)
AU (1) AU2004208505C1 (fr)
BR (1) BRPI0407121B8 (fr)
CA (5) CA2573194A1 (fr)
CR (1) CR7921A (fr)
CY (1) CY1108660T1 (fr)
DE (1) DE602004016967D1 (fr)
DK (1) DK1601359T3 (fr)
EA (1) EA014066B1 (fr)
EC (1) ECSP055938A (fr)
ES (1) ES2315635T3 (fr)
GE (1) GEP20084445B (fr)
HR (1) HRP20050676B1 (fr)
IL (1) IL169859A (fr)
IS (1) IS7984A (fr)
JO (1) JO2735B1 (fr)
MA (1) MA27710A1 (fr)
MX (1) MXPA05008028A (fr)
MY (1) MY144036A (fr)
NO (1) NO329500B1 (fr)
NZ (1) NZ541533A (fr)
PA (1) PA8594801A1 (fr)
PE (1) PE20050066A1 (fr)
PL (1) PL378398A1 (fr)
PT (1) PT1601359E (fr)
PY (1) PY0401585A (fr)
RS (1) RS20050578A (fr)
SI (1) SI1601359T1 (fr)
TN (1) TNSN05180A1 (fr)
TW (1) TWI342212B (fr)
UA (1) UA90449C2 (fr)
UY (1) UY28175A1 (fr)
WO (1) WO2004067005A1 (fr)
ZA (1) ZA200506917B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10393729T5 (de) * 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
CN100336508C (zh) * 2005-02-23 2007-09-12 重庆医药工业研究院有限责任公司 一种稳定的帕洛诺司琼注射液
CN100455286C (zh) * 2006-11-21 2009-01-28 深圳海创医药科技发展有限公司 帕洛诺司琼注射液及其制备方法
WO2008153725A2 (fr) 2007-05-25 2008-12-18 North Carolina State University Plate-forme pour l'apport, ciblé sur des cellules, de nanoparticules virales
US20100048607A1 (en) * 2008-08-25 2010-02-25 Chandrashekhar Kocherlakota Formulations comprising palonosetron
EP2364138A2 (fr) 2008-12-08 2011-09-14 Teva Pharmaceutical Industries Ltd. Formulation de palonosétron
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
CN102781939A (zh) 2009-11-13 2012-11-14 赫尔辛医疗股份公司 帕洛诺司琼代谢物
ES2623503T3 (es) 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente
EP2722045B1 (fr) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions pour traiter les nausées et vomissements à médiation centrale
KR101368587B1 (ko) * 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
CN105412110B (zh) 2011-10-18 2018-05-25 赫尔森保健股份公司 奈妥匹坦和帕洛诺司琼的治疗性组合
CN105934247A (zh) 2013-12-23 2016-09-07 株式会社三养生物制药 包含帕洛诺司琼的药物组合物
CN104784107A (zh) * 2014-01-17 2015-07-22 南京瑞尔医药有限公司 一种盐酸托烷司琼口服液的制备方法
KR20160128573A (ko) * 2015-04-29 2016-11-08 주식회사 삼양바이오팜 약제학적 패키지
CA3025837C (fr) * 2016-06-06 2024-02-13 Helsinn Healthcare Sa Formulations injectables physiologiquement equilibrees de fosnetupitant
JP6768404B2 (ja) * 2016-08-12 2020-10-14 武田テバファーマ株式会社 パロノセトロン又はその薬学的に許容される塩を含む医薬組成物
JP6705348B2 (ja) * 2016-09-23 2020-06-03 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
JP6642377B2 (ja) * 2016-10-25 2020-02-05 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法
KR101802183B1 (ko) * 2016-11-16 2017-11-28 주식회사 유영제약 팔로노세트론을 활성성분으로 함유하는 약제학적 조성물
WO2018112061A1 (fr) 2016-12-15 2018-06-21 Evoke Pharma, Inc. Traitement d'une gastroparésie modérée et grave
EP3672964A4 (fr) 2017-08-21 2021-05-26 Leiutis Pharmaceuticals Pvt. Ltd. Nouvelles formulations à triple combinaison pour une thérapie antiémétique
HRP20230471T1 (hr) * 2018-01-12 2023-07-21 Orion Corporation Palonsetron kapi za oči za liječenje ili prevenciju mučnine i povraćanja
JP7090845B2 (ja) * 2018-08-03 2022-06-27 高田製薬株式会社 パロノセトロン含有液体組成物
JP7438802B2 (ja) * 2020-03-23 2024-02-27 シオノギファーマ株式会社 パロノセトロン含有組成物
TW202428273A (zh) * 2023-01-03 2024-07-16 瑞士商赫爾辛保健公司 奈妥吡坦(netupitant)及帕洛諾司瓊(palonosetron)的液態口服調配物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS599539B2 (ja) * 1979-11-13 1984-03-03 日本化薬株式会社 ニトログリセリン水溶液及びその製造法
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
DE3650772T2 (de) 1985-04-27 2003-04-03 F. Hoffmann-La Roche Ag, Basel Derivate von Indazole-3-carboxamide und -3-carboxylsäure
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
US5578628A (en) 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
GB8516083D0 (en) 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5240954A (en) 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US4906755A (en) 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
US5011846A (en) 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5344658A (en) 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
GB8914804D0 (en) 1989-06-28 1989-08-16 Glaxo Group Ltd Process
PL166267B1 (pl) 1989-11-28 1995-04-28 Syntex Inc Sposób wytwarzania nowych zwiazków trójpierscieniowych PL PL PL PL
JP3222891B2 (ja) 1991-05-03 2001-10-29 ジー．ディー．サール アンド カンパニー 置換ベンゾオキサゼピン化合物、医薬品組成物およびその使用方法
US5272137A (en) 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
GB9305593D0 (en) * 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US5567818A (en) * 1994-07-08 1996-10-22 Syntex (U.S.A.) Inc. Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423588D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
JP3845902B2 (ja) * 1996-07-09 2006-11-15 ソニー株式会社 磁気記録再生装置
ATA156496A (de) 1996-09-03 1997-10-15 Nycomed Austria Gmbh Pharmazeutische zusammensetzung
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
US20030095926A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
GB9721139D0 (en) 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US6294548B1 (en) 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
DE19833119A1 (de) 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
BR9914799A (pt) * 1998-10-27 2001-07-10 Alcon Lab Inc Sistema conservante para composições farmacêuticas administráveis topicamente contendo um sabão de ácido graxo/aminoácido
SK7042003A3 (en) 2000-12-20 2004-07-07 Bristol Myers Squibb Co Substituted pyridoindoles as serotonin agonists and antagonists
KR100921199B1 (ko) 2001-05-11 2009-10-13 미쓰비시 타나베 파마 코퍼레이션 안정하고 고농도인 피라졸론 유도체를 포함하는 주사제
WO2003100091A1 (fr) 2002-05-24 2003-12-04 Epidauros Biotechnologie Ag Moyens et methodes de traitement ameliores utilisant des 'setrones'
DE10393729T5 (de) * 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
WO2004056324A2 (fr) 2002-12-19 2004-07-08 Bristol-Myers Squibb Company Gamma-carbolines tricycliques substituees utilisees comme agonistes et antagonistes du recepteur de la serotonine
JP2006516977A (ja) 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting

Also Published As

Publication number Publication date
CA2514224A1 (fr) 2004-08-12
US20060167073A1 (en) 2006-07-27
ZA200506917B (en) 2006-08-30
CA2573363A1 (fr) 2004-08-12
SI1601359T1 (sl) 2009-04-30
BRPI0407121B8 (pt) 2021-06-29
US20160000773A1 (en) 2016-01-07
GEP20084445B (en) 2008-08-10
EA014066B1 (ru) 2010-08-30
UA90449C2 (ru) 2010-05-11
JP5461763B2 (ja) 2014-04-02
ES2315635T3 (es) 2009-04-01
CA2573228A1 (fr) 2004-08-12
CN1758911A (zh) 2006-04-12
NZ541533A (en) 2008-12-24
PL378398A1 (pl) 2006-04-03
US20140097114A1 (en) 2014-04-10
KR20050104363A (ko) 2005-11-02
TWI342212B (en) 2011-05-21
US20110192493A1 (en) 2011-08-11
JP2011236242A (ja) 2011-11-24
BRPI0407121B1 (pt) 2018-07-17
ATE410167T1 (de) 2008-10-15
HRP20050676B1 (hr) 2013-02-28
EA200501203A1 (ru) 2006-06-30
EP1601359A1 (fr) 2005-12-07
US9457020B2 (en) 2016-10-04
DK1601359T3 (da) 2009-01-05
US7947725B2 (en) 2011-05-24
JO2735B1 (en) 2013-09-15
US20060167071A1 (en) 2006-07-27
AP2005003382A0 (en) 2005-09-30
PY0401585A (es) 2009-12-01
AU2004208505B2 (en) 2009-09-03
EP2008659A1 (fr) 2008-12-31
IS7984A (is) 2005-08-15
US8598218B2 (en) 2013-12-03
US9308266B2 (en) 2016-04-12
AU2004208505A1 (en) 2004-08-12
AU2004208505A2 (en) 2004-08-12
WO2004067005A1 (fr) 2004-08-12
DE602004016967D1 (de) 2008-11-20
IL169859A (en) 2014-11-30
TNSN05180A1 (en) 2007-06-11
AR042977A1 (es) 2005-07-13
ECSP055938A (es) 2006-03-01
MXPA05008028A (es) 2006-01-27
US7947724B2 (en) 2011-05-24
US20140039000A1 (en) 2014-02-06
PA8594801A1 (es) 2004-09-16
BRPI0407121A (pt) 2006-01-10
PE20050066A1 (es) 2005-04-20
KR101113084B1 (ko) 2012-02-15
HRP20050676A2 (en) 2005-10-31
JP5551658B2 (ja) 2014-07-16
PT1601359E (pt) 2008-11-03
MY144036A (en) 2011-07-29
US20130267553A1 (en) 2013-10-10
CN102813621A (zh) 2012-12-12
AP2110A (en) 2010-03-01
CA2514224C (fr) 2009-11-03
CA2573194A1 (fr) 2004-08-12
AU2004208505C1 (en) 2015-10-01
EP1601359B1 (fr) 2008-10-08
US8518981B2 (en) 2013-08-27
NO20053987L (no) 2005-08-26
US20160317440A1 (en) 2016-11-03
NO329500B1 (no) 2010-11-01
CY1108660T1 (el) 2014-04-09
RS20050578A (sr) 2007-09-21
CR7921A (es) 2006-02-07
HK1076401A1 (en) 2006-01-20
UY28175A1 (es) 2004-09-30
US7960424B2 (en) 2011-06-14
CA2573241A1 (fr) 2004-08-12
JP2006516583A (ja) 2006-07-06
US20060069114A1 (en) 2006-03-30
TW200418517A (en) 2004-10-01

Similar Documents

Publication Publication Date Title
MA27710A1 (fr) Formulations pharmaceutiques liquides de palonosetrone
MA38576A1 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
WO2003105800A3 (fr) Forme galenique, se presentant sous forme de film adherant a la muqueuse, pour l'administration de principes actifs du cannabis
MA30470B1 (fr) Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste.
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
CA2431606A1 (fr) Methode et compositions comprenant des formulations qui contiennent des huiles de lecithine et des ains pour proteger le tractus gastro-intestinal et pour fournir une activite therapeutique amelioree
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
MA29681B1 (fr) Formes galeniques du risedronate
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
DK1526839T3 (da) Orale farmaceutiske former for flydende lægemidler med forbedret biotilgængelighed
MA31663B1 (fr) Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe
HUP0105173A2 (hu) Adagolási módszer és készítmény sürgősségi fogamzásgátlásra
CA2101164A1 (fr) Medicaments administrables par voie orale, pour le traitement de la carence en dopamine du systeme nerveux central
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
FR2358162A1 (fr) Compositions pharmaceutiques basiques renfermant un preservateur
ATE427931T1 (de) Analgetische verbindungen, deren synthese und pharmazeutische zusammensetzungen, die diese enthalten
ZA200800180B (en) Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative
AR030039A1 (es) Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento
MA29453B1 (fr) Associations synergiques de medicaments anti-inflammatoires non steroidiens avec des ligands d'alpha-2-delta
MA29333B1 (fr) Preparations pharmaceutiques d'aerosol pour aerosols-doseurs pressurises contenant un agent sequestrant
ATE410152T1 (de) Therapeutisches system mit amoxicillin und clavulansäure
ATE259778T1 (de) Nicht-hygroskopische salze aktiver inhaltsstoffe, die therapeutische und/oder ernährungsphysiologische eigenschaften haben und oral verabreichbare zusammensetzungen, die diese enthalten
MA31744B1 (fr) Compositions pharmaceutiques lyophilisees
WO2020044114A3 (fr) Composition pharmaceutique de méthotrexate